Newron Pharmaceuticals (NWRN) Investor presentation summary

Strategic focus and leadership

• Dedicated to developing innovative treatments for central nervous system (CNS) disorders, aiming to improve patient quality of life.

• Management and board comprise experienced leaders from major pharmaceutical companies, ensuring strong drug development and commercialization expertise.

Product portfolio and pipeline

• Xadago® is approved for Parkinson's disease globally, validating research-to-market capabilities.

• Evenamide is positioned as the first add-on therapy for treatment-resistant schizophrenia (TRS) since clozapine, with a differentiated mechanism of action.

• Evenamide has demonstrated efficacy in both TRS and non-TRS patients in clinical studies.

Clinical evidence and market opportunity

• Evenamide showed positive results in a 1-year pilot study for TRS and a pivotal Phase II/III study for non-TRS patients.

• Large unmet need in schizophrenia, with over 20 million patients worldwide and a market exceeding $23 billion.

• Evenamide’s add-on approach addresses up to 70% of chronic schizophrenia patients inadequately controlled by current therapies.